Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 pharmacokinetic bioequivalence study of DMB-3113 vs adalimumab in healthy Japanese males
jRCT2080223335Phase 1
- Sponsor
- Meiji Seika Pharma Co., Ltd.
- Start
- Sep 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised trial of adalimumab (2 arms), sponsored by Meiji Seika Pharma Co., Ltd. Primary endpoint: Primary pharmacokinetic endpoints.
02
Drugs
Beyond the preview
Go deeper on jRCT2080223335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223335.